Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0158US1	Application No. 10/574,827
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Akira Hayasaka et al.	
		Filing Date	Group Art Unit
		March 27, 2007	1656

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	6,238,891	05/29/2001	Maiorella et al.			
	2	2002/0119530	08/29/2002	Maiorella et al.			
	3	2007/0154469	07/05/2007	Irie et al.			

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner	Desig.	Document	Publication	Country or			Transla	
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	4	EP 0 492 409	07/01/1992	Europe				
	5	WO 89/01975	03/09/1989	WIPO				
	6	WO 89/04867	06/01/1989	WIPO				
	7	WO 03/046162	06/05/2003	WIPO				
	8	WO 2005/005636	01/20/2005	WIPO			English abstract	

	Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.				
Initial	ID	Document			
	9	ARYA et al., "Mapping of Amino Acid Residues in the Cµ3 Domain of Mouse IgM Important in Macromolecular Assembly and Complement-Dependent Cytolysis," <i>J. Immunol.</i> , 152:1206-12 (1994)			
	10	BREWER et al., "Mechanism and Subcellular Localization of Secretory IgM Polymer Assembly," <i>J. Biol. Chem.</i> , 269:17338-48 (1994)			
	11	CATTANEO et al., "Polymeric Immunoglobulin M is Secreted by Transfectants of Non-Lymphoid Cells in the Absence of Immunoglobulin J Chain," <i>EMBO J.</i> , 6:2753-58 (1987)			
	12	GREEN, L., "Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies," <i>J. Immunol. Methods</i> , 231:11-23 (1999)			
	13	HARUTA et al., "Class-Switching of the IgM Type Anit-Adenocarcinoma Human Antibody HB4C5 into an IgG1 Type Resulted in the Loss of the Antigen Binding Ability," <i>Human Antibodies</i> , 8:137-145 (1997)			
	14	HOON et al., "Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers," <i>Cancer Res.</i> , 53:5244-50 (1993)			
	15	HUANG et al., "Production of Recombinant Murine-Human Chimeric IgM and IgG Anti-Js ^b For Use in the Clinical Laboratory," <i>Transfusion</i> , 43:758-764 (2003)			
	16	HUGHEY et al., "Production of IgM Hexamers by Normal and Autoimmune B Cells: Implications for the Physiologic Role of Hexameric IgM," <i>J. Immunol.</i> , 161:4091-97 (1998)			
	17	IRIE et al., "Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma," <i>Cancer Immunol. Immunother.</i> , 53:110-117 (2004)			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no	t in conformance and not considered. Include copy of this form with
next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0158US1	Application No. 10/574,827
Information Disclosure Statement by Applicant		Applicant Akira Hayasaka et al.	
(Use several shee (37 CFR §1.98(b))	ets if necessary)	Filing Date March 27, 2007	Group Art Unit 1656

(Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner	Desig.			
Initial	ID	Document		
		KUNERT et al., "Characterization of Molecular Features, Antigen-Binding, and In Vitro Properties		
	18	of IgG and IgM Variants of 4E10, an Anti-HIV Type 1 Neutralizing Monoclonal Antibody," AIDS		
		Res. Hum. Retroviruses, 20:755-762 (2004)		
	19	MAYUS et al., "Inhibition of <i>In Vitro</i> Anti-DNA B-Cell Responses by Cyclosporine," <i>Cell</i> .		
	17	Immunol., 94:195-204 (1985)		
	20	MENG et al., "J Chain Deficiency in Human IgM Monoclonal Antibodies Produced by Epstein-Barr		
		Virus-Transformed B Lymphocytes," Eur. J. Immunol., 20:2505-08 (1990)		
	21	MONICA et al., "Comparative Biochemical Characterization of a Human IgM Produced in Both		
		Ascites and In Vitro Cell Culture," Biotechnology, 4:512-515 (1993)		
		NILES et al., "Polymer IgM Assembly and Secretion in Lymphoid and Nonlymphoid Cell Lines:		
	22	Evidence that J Chain is Required for Pentamer IgM Synthesis," <i>Proc. Natl. Acad. Sci. USA</i> ,		
		92:2884-88 (1995) RANDALL 44-1 (District Friday That I Chair Beaulass the Beloweric Structure of LM in		
	23	RANDALL et al., "Direct Evidence That J Chain Regulates the Polymeric Structure of IgM in		
		Antibody-secreting B Cells," <i>J. Biol. Chem.</i> , 267:18002-07 (1992) RANDALL et al., "J Chain Synthesis and Secretion of Hexameric IgM is Differentially Regulated		
	24	by Lipopolysaccharide and Interleukin 5," <i>Proc. Natl. Acad. Sci. USA</i> , 89:962-966 (1992)		
		SHITARA et al., "Immunoglobulin Class Switch of Anti-Ganglioside Monoclonal Antibody from		
	25	IgM to IgG," J. Immunol. Methods, 169:83-92 (1994)		
		SORENSEN et al., "Structural Requirements for Incorporation of J Chain into Human IgM and		
	26	IgA," Int. Immunol., 12:19-27 (2000)		
	27	STOCKS et al., "Production and Isolation of Large Quantities of Monoclonal Antibody Using		
	27	Serum-Free Medium and Fast Protein Liquid Chromatography," <i>Hybridoma</i> , 8:241-247 (1989)		
	28	STOLL et al., "Effects of culture conditions on the production and quality of monoclonal IgA,"		
	28	Enzyme Microb. Technol., 21:203-211 (1997)		
	29	TACHIBANA, "Gene expression of joining chain in murine peritoneal B-1 cells," Nihon Univ.		
	29	Dent. J., 76:425-433 (2002) (English abstract included)		
	30	WOOD et al., "High Level Synthesis of Immunoglobulins in Chinese Hamster Ovary Cells," J.		
	30	Immunol., 145:3011-16 (1990)		
	31	YOUD et al., "Synergistic roles of IgM and complement in antigen trapping and follicular		
		localization," Eur. J. Immunol., 32:2328-37 (2002)		
	32	U.S. EXAMINER SHARON X. WEN, USPTO Restriction Requirement in U.S. App. Ser.		
		No. 10/564,665, dated July 9, 2008, 7 pages		
	33	FISH & RICHARDSON P.C., Response to Restriction Requirement dated July 9, 2008, in U.S. App.		
		Ser. No. 10/564,665, filed August 8, 2008, 1 page U.S. EXAMINER ILIA I. OUSPENSKI, USPTO Restriction Requirement in U.S. App. Ser.		
	34	No. 10/564,665, dated November 12, 2008, 6 pages		
		FISH & RICHARDSON P.C., Response to Restriction Requirement dated November 12, 2008, in		
	35	U.S. App. Ser. No. 10/564,665, filed January 9, 2009, 1 page		
		U.S. EXAMINER ILIA I. OUSPENSKI, USPTO Non-Final Office Action in U.S. App. Ser.		
	36	No. 10/564,665, dated April 20, 2009, 16 pages		
		JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/010444,		
	37	mailed October 26, 2004, 4 pages		
	1	7 2 F 0"		

Examiner Signature	Date Considered
Zxariiror digriatare	Data Considered
EVAMINED: Initials sitution considered. Draw line through sitution if no	t in conformance and not considered. Include conv. of this form with
1	of in comormance and not considered. Include copy of this form with
next communication to applicant.	
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	ot in conformance and not considered. Include copy of this form with

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0158US1	Application No. 10/574,827
Information Disclosure Statement by Applicant		Applicant Akira Hayasaka et al.	
(Use several shot) (37 CFR §1.98(b))	eets if necessary)	Filing Date March 27, 2007	Group Art Unit 1656

	Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.				
Initial	ID	Document			
	38	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/010444, dated June 3, 2005, 5 pages			
	39	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/014919, mailed December 7, 2004, 4 pages			
	40	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/014919, dated September 12, 2005, 14 pages			
	41	U.S. EXAMINER SHARON X. WEN, USPTO Restriction Requirement in U.S. App. Ser. No. 10/575,192, dated April 15, 2008, 7 pages			
	42	FISH & RICHARDSON P.C., Response to Restriction Requirement dated April 15, 2008 in U.S. App. Ser. No. 10/575,192, filed September 12, 2008, 1 page			
	43	U.S. EXAMINER SHARON X. WEN, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/575,192, dated January 26, 2009, 11 pages			
	44	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/014935, mailed January 25, 2005, 4 pages			
	45	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/014935, 14 pages			
	46	EUROPEAN EXAMINER PETER BUMB, European Search Report for App. Ser. No. EP 04 79 2204, mailed July 11, 2007, 3 pages			

Examiner Signature	Date Considered
EVANINED In Table of a Consequence of Day Providence of Station Cons	